Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Cancers·2026
Same author

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Cancer·2026
Same author

Improving timing and sequencing of postoperative radiation therapy in head and neck cancer.

Surgery·2026
Same author

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Blood advances·2026
Same author

Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance.

HLA·2026

Related Experiment Video

Updated: Jul 11, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Multiple myeloma: charging toward a bright future.

Jed A Katzel1, Parameswaran Hari, David H Vesole

  • 1St. Vincent's Comprehensive Cancer Center, New York, NY, USA.

CA: a Cancer Journal for Clinicians
|September 15, 2007
PubMed
Summary
This summary is machine-generated.

Significant advancements in diagnosing and treating multiple myeloma (MM), an incurable plasma cell cancer, have been made. New therapies and diagnostic tools are improving patient outcomes and quality of life.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) is a fatal B-cell malignancy affecting approximately 55,000 individuals in the US.
  • Characterized by terminally differentiated plasma cells, MM remains incurable.
  • Recent years have seen substantial progress in MM diagnosis and patient assessment.

Purpose of the Study:

  • To review recent advancements in the diagnosis and treatment of multiple myeloma.
  • To highlight new therapeutic strategies and their impact on patient outcomes.
  • To discuss the evolving landscape of MM management.

Main Methods:

  • Review of recent clinical trials and therapeutic advances in multiple myeloma.
  • Analysis of new diagnostic tools, including simplified staging and free light chain assays.
  • Exploration of emerging targeted therapies and their mechanisms of action.

Main Results:

  • Introduction of a simplified staging system and updated international response criteria.
  • Development of sensitive free light chain assays for improved diagnosis.
  • Recognition of adverse cytogenetic abnormalities guiding personalized treatment.
  • Implementation of novel therapies, including immunomodulatory drugs and proteasome inhibitors.
  • Validation of hematopoietic stem cell transplant and post-transplant maintenance therapy.
  • Emergence of targeted agents and genomics-driven therapies.

Conclusions:

  • Recent breakthroughs have significantly expanded treatment options for multiple myeloma.
  • These advances are leading to prolonged disease control, improved survival rates, and enhanced quality of life for MM patients.
  • The future of MM treatment involves personalized, targeted therapies and a deeper understanding of the tumor microenvironment.